Showing results (961-970 of 1,019) with videos related to
Sort By:
Pageof 102
Clinicoeconomics and Outcomes Research : CEOR|December 29, 2025
Consequences of Canada's Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient AccessNigel S B RawsonClinicoeconomics and Outcomes Research : CEOR|April 21, 2020
Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind StudyEnrico Torre, Giacomo M Bruno, Sergio Di Matteo, et al.Clinicoeconomics and Outcomes Research : CEOR|March 1, 2023
Infrared Thermography Compared to Standard Care in the Prevention and Care of Diabetic Foot: A Cost Analysis Utilizing Real-World Data and an Expert PanelOlli Kurkela, Jorma Lahtela, Martti Arffman, et al.Clinicoeconomics and Outcomes Research : CEOR|December 12, 2025
Cost-Utility Analyses of Hemodialysis, Peritoneal Dialysis, and Kidney Transplantation in Patients with End-Stage Kidney Disease: A Systematic ReviewWening Wulandari, Mohammed Alfaqeeh, Neily Zakiyah, et al.Clinicoeconomics and Outcomes Research : CEOR|February 13, 2015
Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmaciesAmanda L McDonell, Urpo Kiiskinen, Danielle C Zammit, et al.Clinicoeconomics and Outcomes Research : CEOR|March 14, 2015
Cost-effectiveness of using an extensively hydrolyzed casein formula plus the probiotic Lactobacillus rhamnosus GG compared to an extensively hydrolyzed formula alone or an amino acid formula as first-line dietary management for cow's milk allergy in the USOlga Ovcinnikova, Monica Panca, Julian F GuestClinicoeconomics and Outcomes Research : CEOR|April 3, 2015
Erratum: Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece [Corrigendum]Clinicoeconomics and Outcomes Research : CEOR|July 2, 2020
Treatment Options for Cow's Milk Protein Allergy: A Modeling AnalysisMehmet Berktas, Feza Kirbiyik, Elif Aribal, et al.Clinicoeconomics and Outcomes Research : CEOR|July 2, 2020
US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple MyelomaJan Bassali, Ian Gopal Gould, James A Kaye, et al.Clinicoeconomics and Outcomes Research : CEOR|April 15, 2015
The impact of chronic pain on direct medical utilization and costs in chronic obstructive pulmonary diseaseMelissa H Roberts, Douglas W Mapel, Heather N ThomsonPageof 102